Article Text

Download PDFPDF
CD44 expression in papillary serous endometrial carcinoma
  1. S. Hosford*,
  2. J. Elliott,
  3. Z.-W. Ma,
  4. R. Majeste§ and
  5. B. Dubeshter
  1. * Department of Gynecologic Oncology and Pathology, Atlanta, Georgia, New York
  2. § Department of Atlanta Medical Center, Atlanta, Georgia, New York
  3. the Division of Gynecologic Oncology, Rochester, New York
  4. Department of Pathology, University of Rochester School of Medicine, Rochester, New York
  1. Address correspondence and reprint requests to: Brent DuBeshter, MD, 125 Lattimore Road, Rochester, NY 14620. Email: brent_dubeshter{at}


The objective of this paper is to evaluate the relationship between CD44 expression and the clinicopathologic features of papillary serous endometrial cancer. CD44 expression was assessed in 32 cases of papillary serous endometrial carcinoma by standard immunohistochemical staining techniques. Clinicopathologic features including myometrial invasion, nodal metastases, tumor spread, stage, and the shedding of malignant cells on cervical cytology were reviewed. The Chi-square test was used for statistical analysis.

CD44 was not expressed in 81% of patients with papillary serous endometrial carcinoma. Malignant cells were seen on cervical cytology in 68% of all cases with significantly more in the CD44-negative group (78% vs. 33%, P 0.05). CD44 expression was not related to stage, myometrial invasion, nodal involvement, or intraperitoneal spread. We conclude that the cell adhesion molecule CD44 is expressed infrequently in papillary serous endometrial carcinoma. Shedding of malignant cells on cervical cytology is common in papillary serous endometrial cancer and occurs more frequently in CD44-negative cases. CD44 expression doesn't appear to be related to known prognostic features such as nodal metastases or stage. The biologic aggressiveness of this tumor type may, in part, be related to its lack of CD44 expression.

  • CD44
  • papillary serous
  • uterine cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.